drugset / Trial / NCT00131339

Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder

NCT00131339

Completed 40 enrolled Hartford Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This study involves cognitive behavioral therapy (CBT) and a medication called D-cycloserine (DCS), which is thought to help reduce panic symptoms more effectively by interacting with N-methyl-D-aspartate (NMDA) glutamate receptors, facilitating many forms of learning including the extinction of fear. Participants will be randomly assigned (like flipping a coin) to receive either DCS or a placebo in addition to CBT.

Timeline

Start
2004-11
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cycloserine Small molecule

Indications